Norwich Falls To FDA, Bausch, In Bid For Final US Rifaximin Approval

Norwich brought suit against the US Food and Drug Administration in its bid to get final approval for its Xifaxan ANDA product with patent-protected indications carved out, following an earlier patent-infringement decision. Now, a court in Washington DC has had its say.